Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech VC (Venture Capital) Funds in United Kingdom in November 2024

Last updated: Nov 2024 A list of 50 VC (Venture Capital) funds that invest in Biotech startups based in United kingdom. We rank investors based on the number of investments they made in Biotech companies from United kingdom. We update this investor list every month.

Top 50 Biotech VC (Venture Capital) Funds in United Kingdom in November 2024

Investor	Biotech United Kingdom investments
UK Innovation & Science Seed Fund	56
Parkwalk Advisors	43
Oxford Science Enterprises	38
SOSV	37
Scottish Enterprise	37
Oxford Technology Management	35
Oxford Capital	33
Scottish Investment Bank	33
Catapult Ventures	31
Oxford Science Enterprises	26
Mercia Fund Managers	25
Epidarex Capital	22
Development Bank of Wales	22
Archangels	21
Future Planet Capital	21
AlbionVC	20
Newable Private Investing	20
Deepbridge Capital	19
IP Group	18
Sofinnova Partners	18
GM&C Life Sciences Fund	18
Kelvin Capital	17
Cambridge Angels group	17
Octopus Ventures	17
TRICAPITAL	16
O2h Ventures	16
Syncona Partners LLP	16
Par Equity	15
Hoxton Ventures	15
Northstar Ventures	15
Business Growth Fund	14
Wren Capital	14
M Ventures	13
Nesta Ventures	13
Cambridge Innovation Capital	13
24 Haymarket	13
Calculus Capital	13
Wellcome Trust	12
YFM Equity Partners	12
IQ Capital	12
Kindred Capital	12
SFC Capital	12
Longwall Venture	11
Amadeus Capital Partners	11
Meltwind Advisory	11
SR One	11
SyndicateRoom	10
Selvedge Venture	10
Downing Ventures	10
Providence Investment Company Limited	9

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
CryoLogyx — Assay Ready Cells - Discover CryoLogyx's advanced cryopreservation solutions, optimized for cell-based assays in drug discovery. Simply thaw with cell culture medium, and they are ready for use within 24 hours post-thaw.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

CroBio — Crobio presents an environmentally sustainable solution for reducing global water consumption and preventing agricultural drought.
Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
Pencil Biosciences — Next Generation Genome Editing Tool

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

PlantSea — PlantSea manufactures and develops sustainable products using seaweed and aquaculture materials. It offers bioplastics items as biodegradable alternatives. PlantSea is based in Gaerwen, England.
Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Llusern Scientific — Llusern specialises in rapid and affordable near-patient and POC molecular diagnostics developed to detect bacterial and viral infections.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

44.01 — We offer a permanent CO2 storage solution using the natural power of mineralisation
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Wittaya Aqua — A better approach to aquaculture management

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Information Technology
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
tem. — In a few simple steps we can manage your renewable energy needs forever.
Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Chromacity — Chromacity manufacture the next generation of ultrafast lasers. Discover our fixed wavelength femtosecond lasers and picosecond OPOs.
Ingenious Audio — Ingenious Audio is a Scottish start up designing and manufacturing audio electronics."invisible guitar cable" is a compact plug in device which turns an analogue audio product, such as an electric guitar or amplifier into a wi-fi device.This system allows wireless connection of any existing guitar and amplifier; and for the firsttime will allow the use of wireless effect pedals.As the product outputs, wi-fi users can connect seamlessly to any wi-fi enabled pc, replacing the need for expensive recording and audio effects devices and crucially allows sharing of audio across the web.
Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Estonia

Portfolio highlights

xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
Qureight — Pioneering data curation to solve complex diseases
Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Stema — It serves as a platform for hiring engineers

The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series B
United Kingdom, France

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Sellmyartworks — EzelDotz - Buy and Sell Contemporary Art Online | Art Marketplace. Curated collection of Sculptures, Limited Editions and Originals.
Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Pre-Seed
United Kingdom, Hungary

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
ViaNautis — Precision Solutions
Pencil Biosciences — Next Generation Genome Editing Tool

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Purespring Therapeutics — Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Resolution Therapeutics — Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

Founded in 2008, Par Equity is a venture capital firm that backs the most innovative, high growth technology companies in the North of the UK. Based in Edinburgh, Par invests across Northern England, Northern Ireland and Scotland.

Investment focus

Software, Information Technology, Computer
Funding Round, Seed, Series A
United Kingdom, United States, Brazil

Portfolio highlights

Artus — Artus is a revolutionary heating and air conditioning product. Applications include residential, commercial and high-precision environments.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.
Nova Pangaea Technologies (NPT) — NPT is a cleantech company that has developed a revolutionary process technology called REFNOVA. REFNOVA allows customers to converts non-food plant residues into sustainable products such as biochar, activated carbon, biofuel, biopolymers and biochemicals. Our products help customers replace fossil based products and enable decarbonisation.

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Information Technology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.
PACT — PACT designs Elegant materials produced in tune with the planet earth. It create revolutionary, sustainable biomaterials using the earth's resources, including collagen, herbal extracts, oils, and minerals.

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Investment focus

Software, E-Commerce, SaaS
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

FAT32 — FAT32 is at the forefront of compliance automation, transforming the way businesses satisfy regulatory requirements.
Lightox — Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs.
Circadacare — Circadacare helps elderly people and people with dementia live independently for longer with an integrated circadian lighting and home health monitoring system.

BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.

Investment focus

Software, Information Technology, Manufacturing
Funding Round, Series A, Private Equity
United Kingdom, Ireland, United States

Portfolio highlights

Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.
Signify Research — Signify Research provides health tech market intelligence empowered by data.
ER Productions — ER Productions is an innovative laser and SFX specialist providing cutting edge laser and special effects products and choreography to some of the largest shows on earth

Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
PharmEnable — At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
Bastion Therapeutics — Bastion Therapeutics - Enhancing Tregs To Restore Balance In Inflammatory Disorders Treg cell therapy for inflammatory disorders and autoimmune diseases.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
PictorLabs — PictorLabs is a digital pathology company advancing AI-powered virtual staining technology to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence and health-tech product development, the Company is reimagining the ageold practice of histopathology. From a single unstained tissue sample, PictorLabs’ proprietary platform can sustainably produce an unlimited number of virtual stains that are indistinguishable from analogous chemical ones. PictorLabs' technology can replicate standard of care stains and perform specialized virtual biomarker stains for indications that require novel and accelerated diagnostic tests. To learn more, visit https://pictorlabs.ai/ and please follow PictorLabs on LinkedIn.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

We bring bold ideas to life to change the world for good.

Investment focus

Biotechnology, Medical Device, Medical
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
Radio Physics Solutions — Pasar123 website yang paling mudah banget pokoknya untuk mencari scatter hitam yang kalian dambakan itu apalagi kalau bisa dapat 4 scatter di game mahjong wins 3 auto kaya.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — WorkL provides all the resources you need in one location to find employment, advance your career, connect with others, and communicate.
Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
MIP Discovery — MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

YFM Equity Partners is an independent private equity business owned by its senior management and investment team. They invest up to £10 million of equity through offices in Leeds, London, Manchester, Birmingham and Sheffield.

Investment focus

Software, Information Technology, Biotechnology
Funding Round, Private Equity, Series A
United Kingdom, United States, Belgium

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
GEEIQ — GEEIQ: The platform, experts and insights to fuel your success in virtual worlds & gaming. From Roblox and ZEPETO to Minecraft and Fortnite.
Psychology Tools — Psychology Tools publishes evidence-based resources to improve your therapy and save you time. Download CBT worksheets.

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Vsim Technology — Experience the power of next-generation physics simulations with Vsim. Our cutting-edge technology provides realistic and accurate simulations for various industries.
BMLL Technologies — BMLL Technologies Ltd. operates cloud based technology platform that offers machine learning and inference framework for common limit order book problems.

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, Israel, United States

Portfolio highlights

Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Dunia Innovation — Catalysing the energy transition.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

Investment focus

Software, Artificial Intelligence, Information Technology
Pre-Seed, Seed, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

Nesti — An AI-first generative video platform that enables sales teams to deliver 1,000s of personalised outreach videos, on dynamic buyer landing pages, at scale.
Cytix — Cytix is a vulnerability management software platform and cluster of dedicated pentesters to help you identify & resolve Vulnerabilities. Reach us & get a free trial of tool.
Soil Benchmark — Independent software creating Soil Management Plans that tick all the right boxes for SAM1.

Longwall Ventures invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors

Investment focus

Biotechnology, Medical Device, Health Care
Funding Round, Seed, Series A
United Kingdom, Germany, Philippines

Portfolio highlights

Biofidelity — Unleashing the potential of genomics to transform the world we live in through transformational technologies that remove the noise from genomic analysis.
Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.
Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today

Investment focus

Software, Artificial Intelligence, Information Technology
Series B, Seed, Series A
United Kingdom, United States, Spain

Portfolio highlights

PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
qomodo — Intelligent IOT Embedded Security. We protect commercial or industrial IOT devices from the threats of the internet. Driven by leading intelligence and machine learning, our anomaly detection allows us to protect even the simplest IOT devices.

Meltwind Advisory.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Infinitopes — Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
Nomic — Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels.It allowsnanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.

Our EIS and SEIS funds gives investors access to some of the UK's most promising startups. The Access EIS Fund co-invests with leading angel investors to build diversified portfolios based on data, while our SEIS fund lets investors back pre-seed B2B SaaS companies selected and fostered by leading fund Founders Factory.

Investment focus

Health Care, Software, Medical
Seed, Equity Crowdfunding, Funding Round
United Kingdom, United States, India

Portfolio highlights

Heatio — Heatio provides affordable renewable energy to homeowners.
Noggin HQ — The next generation of credit referencing is coming. Look busy.
Unibloom World — Unify targets with operational projects, make scenario simulations with cost impact in real time, compare new ideas, optimise actions and turn it into actionable projects with clear financial, regulations and business impact. Release burden from Sustainability Teams!

Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.

Investment focus

Health Care, Biotechnology, Life Science
Seed, Pre-Seed, Series A
United Kingdom, Singapore

Portfolio highlights

Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.

The opportunity for institutional investors to access leading UK early stage healthtech businesses

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

TidalSense — CRiL was formed in April 2013 specifically to develop innovative medical devices to diagnose and manage respiratory conditions. They have been building a platform technology, N-Tidal, based on the measurement and analysis of tidal breathing CO2 throughout the entire breath.
Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
FundamentalVR — A strategic partner helping med-device leaders solve the Competency @ Scale Gap todrive commercial success.

Providence Investment Company

Investment focus

Biotechnology, Biopharma, Medical
Funding Round, Series B, Seed
United Kingdom

Portfolio highlights

evonetix — Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.
DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Investors by industry